ALNY News and Press, Alnylam Pharmaceuticals Inc. From 10/28/21

Gainers: HCW Biologics (NASDAQ:HCWB) +132%. InflaRx (NASDAQ:IFRX) +45%. Digital Brands Group (NASDAQ:DBGI) +43%. Lucid Group (NASDAQ:LCID) +38%. Wolfspeed (NASDAQ:WOLF) +32%. LendingClub Corporation (NYSE:LC) +32%. Overstock (NASDAQ:OSTK) +25%. Impinj (NASDAQ:PI) +24%. Triterras (NASDAQ:TRIT)...

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were tanking on Thursday after the company reported its earnings results for the third quarter. The biopharmaceutical company's stock is down 14.1% as of 1:34 p.m. EDT, likely due to the company missing revenue estimates for the q...

Gainers: HCW Biologics HCWB +115%, InflaRx IFRX +40%, Inspira Technologies Oxy (NASDAQ:IINN) +37%, Community Health Systems (NYSE:CYH) +16%, Invacare (NYSE:IVC) +11%. Losers: Rafael RFL -80%, DBV Technologies (NASDAQ:DBVT) -13%, Alny...

Shares of Alnylam Pharmaceuticals (ALNY -17.9%) are down in morning trading after the RNAi biotech missed Q3 earnings estimates on both EPS and revenue. Alnylam's YoY net loss narrowed 19% to $204.5M. Net loss per common share went to $1.72 from $2.18. Although revenue grew 49% YoY to $187.6M...

Alnylam Pharmaceuticals (NASDAQ:ALNY) has announced planned CEO leadership transition. Founding Alnylam CEO John Maraganore will hand over the role to Yvonne Greenstreet at year-end 2021. Greenstreet currently serves as the company's President and COO. Maraganore joined Alnylam in 2002 as the...

Alnylam Pharmaceuticals (NASDAQ:ALNY): Q3 Non-GAAP EPS of -$1.51 misses by $0.27; GAAP EPS of -$1.72 misses by $0.15. Revenue of $187.63M (+49.1% Y/Y) misses by $31.06M. Press Release Reiterated 2021 Financial Guidance, Including Combined Net Product Revenues of $640-$665 Million For furthe...

− Achieved Third Quarter 2021 Combined Net Product Revenues of $167 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® – − Reported Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis ...

− Founding Alnylam CEO John Maraganore to Transition CEO Leadership to Alnylam President Yvonne Greenstreet at Year End – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition...

– Vutrisiran Met All 18-Month Secondary Endpoints, Including Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), Gait Speed, Nutritional Status and Overall Disability, Relative to External Placebo – – At Month 18, Vu...

Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI® for the Treatment of Acute Hepatic Porphyria (AHP) in Adults Canada NewsWire -- GIVLAARI reduces Chronic Pain, Improve...